Copyright © 2004, European Society of Cardiology
The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo
Donald W. Reynolds Cardiovascular Research Center, Division of Cardiovascular Medicine, Falk CVRC, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, United States
* Corresponding authors. Tel.: +1 650 723 5013; fax: +1 650 725 2178. Email address: euan{at}stanford.edu tomq1{at}stanford.edu
Objective: The endogenous peptide apelin is differentially regulated in cardiovascular disease but the nature of its role in cardiac function remains unclear.
Methods: We investigated the functional relevance of this peptide using ECG and respiration gated magnetic resonance imaging, conductance catheter pressure–volume hemodynamic measurements, and echocardiography in vivo. In addition, we carried out histology and immunohistochemistry to assess cardiac hypertrophy and to localize apelin and APJ in the adult and embryonic mouse heart.
Results: Intraperitoneal injection of apelin (300 µg/kg) resulted in a decrease in left ventricular end diastolic area (pre: 0.122 ± 0.007; post: 0.104 ± 0.005 cm2, p=0.006) and an increase in heart rate (pre: 537 ± 20; post: 559 ± 19 beats per minute, p=0.03). Hemodynamic measurements revealed a marked increase in ventricular elastance (pre: 3.7 ± 0.9; post: 6.5 ± 1.4 mm Hg/RVU, p=0.018) and preload recruitable stroke work (pre: 27.4 ± 8.0; post: 51.8 ± 3.1, p=0.059) with little change in diastolic parameters following acute infusion of apelin. Chronic infusion (2 mg/kg/day) resulted in significant increases in the velocity of circumferential shortening (baseline: 5.36 ± 0.401; 14 days: 6.85 ± 0.358 circ/s, p=0.049) and cardiac output (baseline: 0.142 ± 0.019; 14 days: 0.25 ± 0.019 l/min, p=0.001) as determined by 15 MHz echocardiography. Post-mortem corrected heart weights were not different between apelin and saline groups (p=0.5) and histology revealed no evidence of cellular hypertrophy in the apelin group (nuclei per unit area, p=0.9). Immunohistochemistry studies revealed APJ staining of myocardial cells in all regions of the adult mouse heart. Antibody staining, as well as quantitative real time polymerase chain reaction identified expression of both APJ and apelin in embryonic myocardium as early as embryonic day 13.5.
Conclusions: Apelin reduces left ventricular preload and afterload and increases contractile reserve without evidence of hypertrophy. These results associate apelin with a positive hemodynamic profile and suggest it as an attractive target for pharmacotherapy in the setting of heart failure.
KEYWORDS Apelin; APJ; Angiotensin; Heart failure; Pressure–volume hemodynamics
Time for primary review 15 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A.P. Weir, K. S. Chong, J. R. Dalzell, C. J. Petrie, C. A. Murphy, T. Steedman, P. B. Mark, T. A. McDonagh, H. J. Dargie, and J. J.V. McMurray Plasma apelin concentration is depressed following acute myocardial infarction in man Eur J Heart Fail, June 1, 2009; 11(6): 551 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Falcao-Pires, N. Goncalves, T. Henriques-Coelho, D. Moreira-Goncalves, R. Roncon-Albuquerque Jr., and A. F. Leite-Moreira Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H2007 - H2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Leeper, M. M. Tedesco, Y. Kojima, G. M. Schultz, R. K. Kundu, E. A. Ashley, P. S. Tsao, R. L. Dalman, and T. Quertermous Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1329 - H1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chandrasekaran, O. Dar, and T. McDonagh The role of apelin in cardiovascular function and heart failure Eur J Heart Fail, August 1, 2008; 10(8): 725 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart Cardiovasc Res, July 15, 2008; 79(2): 279 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azizi, X. Iturrioz, A. Blanchard, S. Peyrard, N. De Mota, N. Chartrel, H. Vaudry, P. Corvol, and C. Llorens-Cortes Reciprocal Regulation of Plasma Apelin and Vasopressin by Osmotic Stimuli J. Am. Soc. Nephrol., May 1, 2008; 19(5): 1015 - 1024. [Full Text] [PDF]
|
|
|
|
|
|
P. Francia, A. Salvati, C. Balla, P. De Paolis, E. Pagannone, M. Borro, G. Gentile, M. Simmaco, L. De Biase, and M. Volpe Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin Eur J Heart Fail, March 1, 2007; 9(3): 306 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Chong, R. S. Gardner, J. J. Morton, E. A. Ashley, and T. A. McDonagh Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure Eur J Heart Fail, June 1, 2006; 8(4): 355 - 360. [Abstract] [Full Text] [PDF]
|
|